Aryx Therapeutics OTC Pink Sheet Today

ARYX
 Stock
  

USD 0.0005  0.00  0.00%   

Market Performance
0 of 100
Odds Of Distress
Less than 40
Aryx Therapeutics is trading at 5.0E-4 as of the 3rd of December 2022; that is No Change since the beginning of the trading day. The stock's open price was 5.0E-4. Aryx Therapeutics has about a 40 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Aryx Therapeutics I are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of November 2022 and ending today, the 3rd of December 2022. Click here to learn more.
CUSIP
043387109
Fiscal Year End
December
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
7th of November 2007
Category
Healthcare
Classification
Health Care
ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. ARYx Therapeutics, Inc. was founded in 1997 and is based in Fremont, California. ARYX THERAPEUTICS operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on PNK Exchange. The company has 33.46 M outstanding shares of which 89.05 K shares are presently shorted by private and institutional investors with about 0.79 trading days to cover. More on Aryx Therapeutics I
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Aryx Therapeutics OTC Pink Sheet Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Aryx Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Aryx Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Aryx Therapeutics generated a negative expected return over the last 90 days
Aryx Therapeutics has some characteristics of a very speculative penny stock
The company has a current ratio of 0.46, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Aryx Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Aryx Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Aryx Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Aryx Therapeutics to invest in growth at high rates of return. When we think about Aryx Therapeutics' use of debt, we should always consider it together with cash and equity.
Net Loss for the year was (33.17 M) with profit before overhead, payroll, taxes, and interest of 0.
Aryx Therapeutics I currently holds about 2.95 M in cash with (34.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Chairman and CEOPaul Goddard
Fama & French Classification
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Aryx Therapeutics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong SellOvervalued
Aryx Therapeutics I [ARYX] is a Pink Sheet which is traded between brokers over the counter. Aryx Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with current market capitalization of 237.58 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Aryx Therapeutics's market, we take the total number of its shares issued and multiply it by Aryx Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Aryx Therapeutics conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 33.46 M outstanding shares of which 89.05 K shares are presently shorted by private and institutional investors with about 0.79 trading days to cover. Aryx Therapeutics I currently holds about 2.95 M in cash with (34.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Aryx Therapeutics Probability Of Bankruptcy
Ownership
Aryx Therapeutics retains a total of 33.46 Million outstanding shares. Almost 100.0 percent of Aryx Therapeutics outstanding shares are held by regular investors with 0.0 (percent) owned by insiders and only 0.14 % by other corporate entities. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Aryx Therapeutics Ownership Details

Aryx Therapeutics Stock Against Markets

Picking the right benchmark for Aryx Therapeutics otc pink sheet is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Aryx Therapeutics otc pink sheet price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Aryx Therapeutics is critical whether you are bullish or bearish towards Aryx Therapeutics I at a given time.
The entity Aryx Therapeutics I with a symbol ARYX was recently relisted or delisted. You can potentially use Aryx Therapeutics I with a symbol ARYX. Please make sure the ticker renaming or change in the classification of Aryx Therapeutics I is not a temporary action by the exchange.

Aryx Therapeutics Corporate Executives

Elected by the shareholders, the Aryx Therapeutics' board of directors comprises two types of representatives: Aryx Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aryx Therapeutics. The board's role is to monitor Aryx Therapeutics' management team and ensure that shareholders' interests are well served. Aryx Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aryx Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.

Invested in Aryx Therapeutics I?

The danger of trading Aryx Therapeutics I is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aryx Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aryx Therapeutics. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aryx Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please continue to Trending Equities. You can also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Complementary Tools for analysis

When running Aryx Therapeutics price analysis, check to measure Aryx Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aryx Therapeutics is operating at the current time. Most of Aryx Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aryx Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Aryx Therapeutics' price. Additionally, you may evaluate how the addition of Aryx Therapeutics to your portfolios can decrease your overall portfolio volatility.
Transaction History
View history of all your transactions and understand their impact on performance
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Please note, there is a significant difference between Aryx Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Aryx Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aryx Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.